| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.19B | 7.33B | 7.24B | 8.53B | 6.15B |
| Gross Profit | 729.39M | 938.00M | 710.00M | 963.00M | 664.00M |
| EBITDA | 720.88M | 542.00M | 605.00M | 539.00M | 764.00M |
| Net Income | 232.35M | 56.00M | 125.00M | 308.00M | 257.00M |
Balance Sheet | |||||
| Total Assets | 4.56B | 4.73B | 4.66B | 5.27B | 5.26B |
| Cash, Cash Equivalents and Short-Term Investments | 102.13M | 141.00M | 210.00M | 177.16M | 167.17M |
| Total Debt | 1.65B | 1.94B | 1.87B | 2.19B | 2.42B |
| Total Liabilities | 3.73B | 4.01B | 3.80B | 4.47B | 4.93B |
| Stockholders Equity | 810.25M | 706.00M | 843.00M | 780.16M | 311.59M |
Cash Flow | |||||
| Free Cash Flow | 135.32M | -112.00M | 66.00M | 186.02M | 125.00M |
| Operating Cash Flow | 416.19M | 301.00M | 432.00M | 472.94M | 357.00M |
| Investing Cash Flow | -268.95M | -318.00M | -219.00M | -285.87M | -221.00M |
| Financing Cash Flow | -177.03M | -56.00M | -174.00M | -168.16M | -435.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $17.26B | 12.08 | 18.80% | 0.75% | 20.08% | ― | |
67 Neutral | $3.00B | 34.48 | 8.14% | 0.43% | 3.93% | -73.94% | |
65 Neutral | $5.59B | 88.30 | 5.54% | ― | 20.15% | -72.89% | |
65 Neutral | $1.94B | 16.51 | 14.22% | 2.64% | 7.69% | 91.86% | |
64 Neutral | $3.40B | 9.64 | 29.22% | ― | 8.48% | 12.10% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | $2.39B | -12.82 | -38.91% | ― | -13.39% | 88.25% |
On March 12, 2026, Constellium announced that its Board of Directors authorized a new share repurchase program of up to $300 million of outstanding ordinary shares, effective after the May 21, 2026 Annual General Meeting and running through December 31, 2028. The plan replaces a buyback program approved in February 2024, with the company continuing to repurchase shares under the existing authorization until the new one takes effect.
Management framed the program as part of a balanced capital allocation strategy aimed at returning cash to shareholders while preserving flexibility. The company may execute repurchases in open market or privately negotiated transactions, including via Rule 10b5-1 plans, with timing and volume contingent on market conditions and other capital allocation priorities, and the Board retaining the right to modify or terminate the program, subject to annual shareholder approvals at future meetings.
The most recent analyst rating on (CSTM) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Constellium stock, see the CSTM Stock Forecast page.